Merck (NYSE:MRK) announces that Keytruda has been approved by the National Medical Products Administration in China as a lung cancer treatment.
The company says the approval is the third for first-line NSCLC in China.
Keytruda in combination with chemotherapy significantly was found to improve both overall survival and progression-free survival in patients with metastatic squamous non-small cell lung cancer.
MRK +0.53% premarket to $86.15.
Source: Press Release
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.